CheckMate 649 | Clinical Trials Search

829 results for “CheckMate 649”

Need more precision?

Filter by phase, recruitment status, country, sponsor, age, and study type.

Refine trial search

Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

116 participants · First posted Jan 17, 2014

Active, not recruiting

Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases

810 participants · First posted Mar 20, 2026

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

138 participants · First posted Feb 5, 2013

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

1,096 participants · First posted Sep 4, 2014

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

361 participants · First posted Apr 7, 2014

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

945 participants · First posted May 1, 2013

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

351 participants · First posted Dec 7, 2016

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

821 participants · First posted Aug 20, 2012

A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)

124 participants · First posted Jun 15, 2022

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

194 participants · First posted Nov 16, 2011

Page 1 of 37